Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (now Sanofi-Aventis) dated August 12, 2004, reports the definitive results of its public offers to acquire Aventis. The filing confirms the successful conclusion of the initial offering period which expired on July 30, 2004, and announces the commencement of a subsequent offering period from August 13, 2004, to September 6, 2004.
Key Financial and Transaction Metrics
- Ownership Stake: Sanofi-Synthelabo holds 95.47% of Aventis share capital and 95.52% of voting rights following the initial offer.
- Shares Tendered: 769,920,773 Aventis ordinary shares and 257,248 warrants were tendered.
- Fully Diluted Basis: Post-offer, Sanofi-Synthelabo will hold 89.84% of share capital and 89.88% of voting rights.
- Consideration Allocation: Due to oversubscription of the all-cash election, the final consideration for cash electors is approximately €21.89 in cash plus 0.7872 Sanofi-Synthelabo shares per Aventis share.
- Dividend Information: New shares issued in the exchange will be entitled to a €1.02 dividend (approved for 2003 results), payable on or about September 30, 2004.
Material Changes and Transaction Status
The filing confirms that the minimum tender conditions were satisfied, rendering the offers successful. Sanofi-Synthelabo will accept all tendered shares and warrants. Settlement for tendered ordinary shares is expected on August 20, 2004, with U.S. ADS settlement by August 26, 2004. Upon settlement, Aventis will become a controlled subsidiary, and Sanofi-Synthelabo will officially change its name to "Sanofi-Aventis."
Outlook, Management Commentary, and Risks
- Subsequent Offering: A 17-day subsequent offering period is open to remaining shareholders with identical terms to the initial offer.
- Future Actions: No decision has yet been made regarding a minority buy-out offer, compulsory acquisition, or a formal merger of the two entities.
- Corporate Governance: Eight directors proposed by Aventis will take office on August 20, 2004, including Jean-Marc Bruel and Jean-Rene Fourtou.
- Risks: Forward-looking statements are subject to risks including U.S. market expansion profitability, R&D success, intellectual property protection, and healthcare reimbursement/pricing reforms.
Investor Verification Checklist
- Verify the final settlement dates for cash and stock consideration (August 20 and August 26, 2004).
- Confirm the exact consideration received if an "all cash" election was made, noting the proration adjustment to €21.89 cash plus stock.
- Monitor announcements regarding the subsequent offering period results expected around September 16, 2004.
- Check for future filings regarding the decision on minority buy-out or formal merger procedures.
- Review the Form F-4 Registration Statement (No. 333-112314) for detailed offer terms and risk factors.